There has been rapid development in the field of pharmacogenetics and pharmacogenomics in experimental research with the recent implementation of novel methods to identify and target genes. This refers to both hereditary conditions and those associated with increased toxicity to drugs and substances. However, there is a gap between the advances observed in basic science in the lab with their application to everyday use in clinics. This is predominantly a result of the long implementation processes for any techniques for clinical practice and the requirement of associated clinical trials and approval. As a result, there are a larger proportion of studies published at the stage of experimental testing and exploratory studies, compared with publications of trials at the stage of clinical use. Attempts are being made to bridge this gap and they are the main focus of this Research Topic.
This Research Topic specifically targets those cutting-edge technologies that are making their first steps into clinics, but there are little to no clinical trials yet published.
This Research Topic welcomes original research, including clinical trials, and review articles covering, but not limited to, the following topics:
- Implementation of genetic testing to guide antithrombotic treatment
- Implementation of genetic testing to guide antipsychotics use
- Implementation of decision-support systems to guide a treatment plan
-MicroRNA utilisation as biomarkers of the effectiveness of treatment RNA-seq Cap analysis of gene expression (CAGE-seq)
Articles acceptable for this Research Topic are limited to:
- Articles unambiguously related to pharmacogenetics, pharmacogenomics, drug metabolism, or drug transport.
- If patient data are analyzed, a comprehensive description of the patients including sex, ethnicity, diagnostic criteria, and assessment of drug response/effects should be included.
- If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the selection of the specific data studied should be provided.
- Only articles involving highly purified, chemically characterized compounds will be included. Studies related to natural compounds, herbal extracts, or traditional medicine products, will not be included in this Research Topic.
There has been rapid development in the field of pharmacogenetics and pharmacogenomics in experimental research with the recent implementation of novel methods to identify and target genes. This refers to both hereditary conditions and those associated with increased toxicity to drugs and substances. However, there is a gap between the advances observed in basic science in the lab with their application to everyday use in clinics. This is predominantly a result of the long implementation processes for any techniques for clinical practice and the requirement of associated clinical trials and approval. As a result, there are a larger proportion of studies published at the stage of experimental testing and exploratory studies, compared with publications of trials at the stage of clinical use. Attempts are being made to bridge this gap and they are the main focus of this Research Topic.
This Research Topic specifically targets those cutting-edge technologies that are making their first steps into clinics, but there are little to no clinical trials yet published.
This Research Topic welcomes original research, including clinical trials, and review articles covering, but not limited to, the following topics:
- Implementation of genetic testing to guide antithrombotic treatment
- Implementation of genetic testing to guide antipsychotics use
- Implementation of decision-support systems to guide a treatment plan
-MicroRNA utilisation as biomarkers of the effectiveness of treatment RNA-seq Cap analysis of gene expression (CAGE-seq)
Articles acceptable for this Research Topic are limited to:
- Articles unambiguously related to pharmacogenetics, pharmacogenomics, drug metabolism, or drug transport.
- If patient data are analyzed, a comprehensive description of the patients including sex, ethnicity, diagnostic criteria, and assessment of drug response/effects should be included.
- If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the selection of the specific data studied should be provided.
- Only articles involving highly purified, chemically characterized compounds will be included. Studies related to natural compounds, herbal extracts, or traditional medicine products, will not be included in this Research Topic.
